Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of LY2623091 with CYP3A Modulators
NCT02300259Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LY-2623091 in hypertension (HTN) and chronic kidney disease (CKD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Drug Concentration of LY2623091 at Day 6, Area Under the Concentration Versus Time Curve of LY2623091 at Day 6 and 2 more. Started Nov 2014; status: completed.
02
Drugs
LY-2623091
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02300259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300259.